Srikanth Venkatraman - Disc Medicine Senior Chemistry
| IRON Stock | 64.96 1.45 2.28% |
Executive
Srikanth Venkatraman is Senior Chemistry of Disc Medicine
| Address | 321 Arsenal Street, Watertown, MA, United States, 02472 |
| Phone | 617 674 9274 |
| Web | https://www.discmedicine.com |
Disc Medicine Management Efficiency
The company has return on total asset (ROA) of (0.1791) % which means that it has lost $0.1791 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.2503) %, meaning that it created substantial loss on money invested by shareholders. Disc Medicine's management efficiency ratios could be used to measure how well Disc Medicine manages its routine affairs as well as how well it operates its assets and liabilities. As of the 23rd of November 2024, Return On Tangible Assets is likely to drop to -0.22. In addition to that, Return On Capital Employed is likely to drop to -0.28. At this time, Disc Medicine's Other Assets are very stable compared to the past year. As of the 23rd of November 2024, Total Current Assets is likely to grow to about 383.9 M, while Total Assets are likely to drop about 215.2 M.Similar Executives
| Showing other executives | EXECUTIVE Age | ||
| Jessica Ibbitson | Mineralys Therapeutics, Common | N/A | |
| Adam JD | Day One Biopharmaceuticals | 57 | |
| Lani Ibarra | Structure Therapeutics American | N/A | |
| Pamela Danagher | Terns Pharmaceuticals | N/A | |
| Hui Lei | Structure Therapeutics American | N/A | |
| Benjamin Stone | AnaptysBio | N/A | |
| Debra Sieminski | Terns Pharmaceuticals | N/A | |
| Patrick MD | Centessa Pharmaceuticals PLC | N/A | |
| Juan MD | Biomea Fusion | N/A | |
| Christiana MBA | Fennec Pharmaceuticals | N/A | |
| Terry Evans | Fennec Pharmaceuticals | N/A | |
| Tammy Sarnelli | Amylyx Pharmaceuticals | N/A | |
| Camille MD | Amylyx Pharmaceuticals | 71 | |
| Minji MBA | Mineralys Therapeutics, Common | N/A | |
| Julie Dexter | Olema Pharmaceuticals | N/A | |
| MaryAlice JD | Acrivon Therapeutics, Common | 50 | |
| James MD | AnaptysBio | 62 | |
| MSc MD | Centessa Pharmaceuticals PLC | 66 | |
| Elly MD | Day One Biopharmaceuticals | N/A | |
| Xiaohong She | Adagene | 57 | |
| Dana MD | Crinetics Pharmaceuticals | 68 | |
Management Performance
| Return On Equity | -0.25 | ||||
| Return On Asset | -0.18 |
Disc Medicine Leadership Team
Elected by the shareholders, the Disc Medicine's board of directors comprises two types of representatives: Disc Medicine inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Disc. The board's role is to monitor Disc Medicine's management team and ensure that shareholders' interests are well served. Disc Medicine's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Disc Medicine's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Jonathan Yu, Chief Officer | ||
| Rahul Kaushik, Chief Officer | ||
| Donald Nicholson, Independent Chairman | ||
| Joanne CPA, Chief Officer | ||
| William MD, Chief Officer | ||
| Pamela MPH, Chief Officer | ||
| Jean CPA, Chief Officer | ||
| Hua Yang, Senior Pharmacology | ||
| Jean Franchi, Chief Officer | ||
| Srikanth Venkatraman, Senior Chemistry | ||
| Esq JD, President CEO | ||
| Jonathan MBA, Chief Officer | ||
| ChB MB, Founder Board | ||
| PharmD JD, Compliance Counsel |
Disc Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Disc Medicine a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -0.25 | ||||
| Return On Asset | -0.18 | ||||
| Current Valuation | 1.4 B | ||||
| Shares Outstanding | 29.76 M | ||||
| Shares Owned By Insiders | 12.47 % | ||||
| Shares Owned By Institutions | 97.73 % | ||||
| Number Of Shares Shorted | 1.63 M | ||||
| Price To Book | 4.04 X | ||||
| EBITDA | (91.03 M) | ||||
| Net Income | (76.43 M) |
Pair Trading with Disc Medicine
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Disc Medicine position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Disc Medicine will appreciate offsetting losses from the drop in the long position's value.Moving against Disc Stock
| 0.78 | PFE | Pfizer Inc Aggressive Push | PairCorr |
| 0.76 | TCHH | Trustcash Holdings | PairCorr |
| 0.73 | JNJ | Johnson Johnson Sell-off Trend | PairCorr |
| 0.65 | MRK | Merck Company Fiscal Year End 6th of February 2025 | PairCorr |
| 0.6 | AGL | agilon health | PairCorr |
The ability to find closely correlated positions to Disc Medicine could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Disc Medicine when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Disc Medicine - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Disc Medicine to buy it.
The correlation of Disc Medicine is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Disc Medicine moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Disc Medicine moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Disc Medicine can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in Disc Medicine. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in persons. To learn how to invest in Disc Stock, please use our How to Invest in Disc Medicine guide.You can also try the Sectors module to list of equity sectors categorizing publicly traded companies based on their primary business activities.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Disc Medicine. If investors know Disc will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Disc Medicine listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (3.95) | Return On Assets (0.18) | Return On Equity (0.25) |
The market value of Disc Medicine is measured differently than its book value, which is the value of Disc that is recorded on the company's balance sheet. Investors also form their own opinion of Disc Medicine's value that differs from its market value or its book value, called intrinsic value, which is Disc Medicine's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Disc Medicine's market value can be influenced by many factors that don't directly affect Disc Medicine's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Disc Medicine's value and its price as these two are different measures arrived at by different means. Investors typically determine if Disc Medicine is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Disc Medicine's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.